Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ICPT's Cash to Debt is ranked higher than
78% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. ICPT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ICPT' s Cash to Debt Range Over the Past 10 Years
Min: 218.39  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.80
ICPT's Equity to Asset is ranked higher than
64% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ICPT: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
ICPT' s Equity to Asset Range Over the Past 10 Years
Min: -1.08  Med: 0.75 Max: 0.96
Current: 0.8
-1.08
0.96
Interest Coverage No Debt
ICPT's Interest Coverage is ranked higher than
69% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ICPT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ICPT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 19.31
M-Score: -3.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -5049.15
ICPT's Operating margin (%) is ranked lower than
89% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. ICPT: -5049.15 )
Ranked among companies with meaningful Operating margin (%) only.
ICPT' s Operating margin (%) Range Over the Past 10 Years
Min: -8237.1  Med: -2432.31 Max: -766.2
Current: -5049.15
-8237.1
-766.2
Net-margin (%) -5004.71
ICPT's Net-margin (%) is ranked lower than
89% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. ICPT: -5004.71 )
Ranked among companies with meaningful Net-margin (%) only.
ICPT' s Net-margin (%) Range Over the Past 10 Years
Min: -16258.67  Med: -4179.53 Max: -705.71
Current: -5004.71
-16258.67
-705.71
ROE (%) -59.00
ICPT's ROE (%) is ranked lower than
66% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. ICPT: -59.00 )
Ranked among companies with meaningful ROE (%) only.
ICPT' s ROE (%) Range Over the Past 10 Years
Min: -180.8  Med: -118.75 Max: -54.36
Current: -59
-180.8
-54.36
ROA (%) -52.89
ICPT's ROA (%) is ranked lower than
70% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. ICPT: -52.89 )
Ranked among companies with meaningful ROA (%) only.
ICPT' s ROA (%) Range Over the Past 10 Years
Min: -140.05  Med: -66.3 Max: -49.77
Current: -52.89
-140.05
-49.77
ROC (Joel Greenblatt) (%) -3209.02
ICPT's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. ICPT: -3209.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ICPT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8893.89  Med: -4333 Max: -2882.65
Current: -3209.02
-8893.89
-2882.65
Revenue Growth (3Y)(%) -33.00
ICPT's Revenue Growth (3Y)(%) is ranked lower than
80% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. ICPT: -33.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ICPT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -46.3 Max: -33
Current: -33
EBITDA Growth (3Y)(%) 47.70
ICPT's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ICPT: 47.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ICPT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.9  Med: 10.4 Max: 47.7
Current: 47.7
-22.9
47.7
EPS Growth (3Y)(%) 9.10
ICPT's EPS Growth (3Y)(%) is ranked higher than
66% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. ICPT: 9.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ICPT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.4  Med: 9.1 Max: 42.3
Current: 9.1
-11.4
42.3
» ICPT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ICPT Guru Trades in Q3 2015

Jim Simons 61,600 sh (+0.33%)
Columbia Wanger 209,818 sh (-23.89%)
» More
Q4 2015

ICPT Guru Trades in Q4 2015

George Soros 2,800 sh (New)
Jim Simons Sold Out
Columbia Wanger 186,872 sh (-10.94%)
» More
Q1 2016

ICPT Guru Trades in Q1 2016

Steven Cohen 10,300 sh (New)
Columbia Wanger 187,043 sh (+0.09%)
George Soros Sold Out
» More
Q2 2016

ICPT Guru Trades in Q2 2016

George Soros 8,100 sh (New)
Columbia Wanger 233,573 sh (+24.88%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ICPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:TECH, NAS:ACAD, NAS:IONS, NAS:EXEL, NAS:CBPO, NAS:GLPG, OTCPK:BTGGF, NYSE:XON, NAS:JUNO, NAS:RARE, OTCPK:SOLTF, NAS:GRFS, NAS:SRPT, NAS:KITE, NAS:UTHR, NAS:BLUE, NAS:TSRO, OTCPK:LBTSF, NAS:ARIA, NAS:NKTR » details
Traded in other countries:I4P.Germany,
Intercept Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry.

Intercept Pharmaceuticals Inc was incorporated in the State of Delaware on September 4, 2002. It is a biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry. The Company's product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. The Company's product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which it believes has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial that it anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. The Company currently expects results from the trial to be available by mid-2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC. The Company owns the rights to OCA outside of Japan and China, where it has exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Some of the competitors are Eli Lilly, Exelixis, Inc. and Phenex Pharmaceuticals AG. Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those it is developing.

Ratios

vs
industry
vs
history
P/B 10.02
ICPT's P/B is ranked lower than
83% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ICPT: 10.02 )
Ranked among companies with meaningful P/B only.
ICPT' s P/B Range Over the Past 10 Years
Min: 3.99  Med: 9.53 Max: 104.9
Current: 10.02
3.99
104.9
P/S 605.71
ICPT's P/S is ranked lower than
94% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. ICPT: 605.71 )
Ranked among companies with meaningful P/S only.
ICPT' s P/S Range Over the Past 10 Years
Min: 42.02  Med: 1513.49 Max: 5193.93
Current: 605.71
42.02
5193.93
Current Ratio 4.95
ICPT's Current Ratio is ranked higher than
52% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. ICPT: 4.95 )
Ranked among companies with meaningful Current Ratio only.
ICPT' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 14.84 Max: 31.15
Current: 4.95
0.48
31.15
Quick Ratio 4.95
ICPT's Quick Ratio is ranked higher than
53% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ICPT: 4.95 )
Ranked among companies with meaningful Quick Ratio only.
ICPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 14.84 Max: 31.15
Current: 4.95
0.48
31.15

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.80
ICPT's 3-Year Average Share Buyback Ratio is ranked lower than
58% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ICPT: -13.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -86  Med: -79.9 Max: -13.8
Current: -13.8
-86
-13.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.80
ICPT's Price/Net Cash is ranked lower than
69% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. ICPT: 12.80 )
Ranked among companies with meaningful Price/Net Cash only.
ICPT' s Price/Net Cash Range Over the Past 10 Years
Min: 6.12  Med: 10.59 Max: 20.35
Current: 12.8
6.12
20.35
Price/Net Current Asset Value 10.68
ICPT's Price/Net Current Asset Value is ranked lower than
68% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. ICPT: 10.68 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ICPT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 6.06  Med: 9.56 Max: 19.86
Current: 10.68
6.06
19.86
Price/Tangible Book 10.20
ICPT's Price/Tangible Book is ranked lower than
75% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. ICPT: 10.20 )
Ranked among companies with meaningful Price/Tangible Book only.
ICPT' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.94  Med: 9.41 Max: 19.33
Current: 10.2
5.94
19.33
Price/Median PS Value 0.41
ICPT's Price/Median PS Value is ranked higher than
87% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. ICPT: 0.41 )
Ranked among companies with meaningful Price/Median PS Value only.
ICPT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.89 Max: 2.45
Current: 0.41
0.03
2.45
Earnings Yield (Greenblatt) (%) -9.18
ICPT's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. ICPT: -9.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ICPT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.01  Med: 0 Max: 0
Current: -9.18
-13.01
0

More Statistics

Revenue (TTM) (Mil) $6.86
EPS (TTM) $ -14.08
Beta-2.38
Short Percentage of Float41.81%
52-Week Range $89.76 - 217.99
Shares Outstanding (Mil)24.73

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 19 108 380 745
EPS ($) -16.15 -14.25 -6.14 4.70
EPS w/o NRI ($) -16.15 -14.25 -6.14 4.70
EPS Growth Rate
(3Y to 5Y Estimate)
3.00%
Dividends Per Share ($)
» More Articles for ICPT

Headlines

Articles On GuruFocus.com
Intercept Pharmaceuticals Inc (ICPT) Moves Forward With OCA REGENERATE Trial; Buy Why Did Shares Sli May 20 2015 
Analysts are Positive on Intercept Pharmaceuticals Inc Following Quarterly Earnings and Pipeline Upd May 12 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST Mar 30 2015 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc, Ross Stores Inc, Sally Beauty Holdings In Mar 30 2015 
Intercept Pharmaceuticals Announces Two New Sub-Groups for FLINT Trial Mar 24 2015 
Intercept Pharma’s Losses Widen, but Revenue Rises Mar 03 2015 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Intercept Pharmaceuticals (ICPT) Obeticholic Acid Momentum, Gigamon (GIMO) Robust Revenue Growth Jan 30 2015 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 

More From Other Websites
Intercept Pharmaceuticals Inc (ICPT) CEO & President Mark Pruzanski Sold $5.8 million of Shares Sep 22 2016
Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle Sep 22 2016
Gilead Sciences: A Hidden Asset? Sep 22 2016
5 Biotech Stocks to Watch as Interest in NASH Increases Sep 22 2016
[$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal Sep 20 2016
Big Pharma, Biotech Attack NASH Liver Illness From All Sides Sep 20 2016
[$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal Sep 20 2016
Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm Sep 20 2016
Biotech buyout: The next big liver disease Sep 20 2016
Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm Sep 20 2016
Allergan: What is It Thinking?!?! Sep 20 2016
Gilead Sciences: Why Allergan's Tobira Purchase is Wonderful, Wonderful News Sep 20 2016
Intercept Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ICPT) : September 20, 2016 Sep 20 2016
Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US :... Sep 19 2016
Intercept Pharmaceuticals Files New Drug Submission to Health Canada for Marketing Approval of... Sep 19 2016
Intercept Pharmaceuticals Files New Drug Submission to Health Canada for Marketing Approval of... Sep 19 2016
INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other Events Sep 12 2016
Intercept to Present at Upcoming Investor Conferences Sep 02 2016
Intercept to Present at Upcoming Investor Conferences Sep 02 2016
17 Questions for Gilead Sciences Aug 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)